Views & Analysis Who needs (early) advice? You do! The prospects for HTA Early Scientific Advice programmes.
News Tecentriq is best value lung cancer immunotherapy, concludes... Roche/Genentech’s Tecentriq represents the best value for money among the new generation of immunotherapy treatments for lung cancer – but is still overpriced.
Views & Analysis Patient-centricity and pharma: where are we now? How should the industry define patient-centricity, and how should progress be measured?
News UK must draw up post-Brexit pharma strategy Big pharma could take its money elsewhere post Brexit, report warns.
Views & Analysis Flexible models for better access Which initiatives are the most likely to bring life-changing therapies to patients?
Views & Analysis Steering through the healthcare revolution Disruptive factors are forcing pharma companies to reassess and redefine how they do business.
Oncology Getting predictive technologies to patients, with Concr Dr Irina Babina, CEO of oncology R&D platform Concr, discusses how current regulatory frameworks were built for static diagnostics.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
